NUWE Quote, Financials, Valuation and Earnings

Hologic has a net margin of -63.22% compared to Nuwellis's net margin of 19.67%. Nuwellis's return on equity of -800.59% beat Hologic's return on equity of 15.28%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 1040.35%. On the other hand Hologic has an analysts' consensus of $78.66 which suggests that it could grow by 27.09%. Given that Nuwellis has higher upside potential than Hologic, analysts believe Nuwellis is more attractive than Hologic.

Nuwellis has a beta of 0.359, which suggesting that the stock is 64.091% less volatile than S&P 500. In comparison Hologic has a beta of 0.971, suggesting its less volatile than the S&P 500 by 2.862%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.3M, which are smaller than Hologic quarterly revenues of $1B. Nuwellis's net income of -$1.5M is lower than Hologic's net income of $201M. Notably, Nuwellis's price-to-earnings ratio is -- while Hologic's PE ratio is 19.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.21x versus 3.61x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -63.22% compared to Nuwellis's net margin of -2.16%. Nuwellis's return on equity of -800.59% beat Myomo's return on equity of -48.64%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 1040.35%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 67.57%. Given that Nuwellis has higher upside potential than Myomo, analysts believe Nuwellis is more attractive than Myomo.

Nuwellis has a beta of 0.359, which suggesting that the stock is 64.091% less volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.3M, which are smaller than Myomo quarterly revenues of $12.1M. Nuwellis's net income of -$1.5M is lower than Myomo's net income of -$260.1K. Notably, Nuwellis's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.21x versus 6.40x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Quanterix has a net margin of -63.22% compared to Nuwellis's net margin of -34.09%. Nuwellis's return on equity of -800.59% beat Quanterix's return on equity of -11.35%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 1040.35%. On the other hand Quanterix has an analysts' consensus of $14.50 which suggests that it could grow by 101.67%. Given that Nuwellis has higher upside potential than Quanterix, analysts believe Nuwellis is more attractive than Quanterix.

Nuwellis has a beta of 0.359, which suggesting that the stock is 64.091% less volatile than S&P 500. In comparison Quanterix has a beta of 1.336, suggesting its more volatile than the S&P 500 by 33.57%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quanterix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Quanterix pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.3M, which are smaller than Quanterix quarterly revenues of $34.1M. Nuwellis's net income of -$1.5M is higher than Quanterix's net income of -$11.6M. Notably, Nuwellis's price-to-earnings ratio is -- while Quanterix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.21x versus 2.04x for Quanterix. Usually stocks with elevated PS ratios are considered overvalued.

Varex Imaging has a net margin of -63.22% compared to Nuwellis's net margin of -0.15%. Nuwellis's return on equity of -800.59% beat Varex Imaging's return on equity of -8.27%.

Nuwellis has a consensus price target of $13.00, signalling upside risk potential of 1040.35%. On the other hand Varex Imaging has an analysts' consensus of $21.20 which suggests that it could grow by 68.66%. Given that Nuwellis has higher upside potential than Varex Imaging, analysts believe Nuwellis is more attractive than Varex Imaging.

Nuwellis has a beta of 0.359, which suggesting that the stock is 64.091% less volatile than S&P 500. In comparison Varex Imaging has a beta of 0.563, suggesting its less volatile than the S&P 500 by 43.729%.

Nuwellis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Varex Imaging offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nuwellis pays -- of its earnings as a dividend. Varex Imaging pays out -- of its earnings as a dividend.

Nuwellis quarterly revenues are $2.3M, which are smaller than Varex Imaging quarterly revenues of $199.8M. Nuwellis's net income of -$1.5M is lower than Varex Imaging's net income of -$300K. Notably, Nuwellis's price-to-earnings ratio is -- while Varex Imaging's PE ratio is 17.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nuwellis is 0.21x versus 0.63x for Varex Imaging. Usually stocks with elevated PS ratios are considered overvalued.